NASDAQ:MRKR

Marker Therapeutics Stock Forecast, Price & News

$2.07

-0.06 (-2.82 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.02

Now: $2.07▼

$2.18

50-Day Range

$1.45

MA: $1.64▼

$2.13

52-Week Range

$1.32

Now: $2.07▼

$3.39

Volume640,025 shs

Average Volume887,843 shs

Market Capitalization$99.41 million

P/E RatioN/A

Dividend YieldN/A

Beta1.27

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Overall MarketRank^™

1.14 out of 5 stars

Medical Sector

743rd out of 1,480 stocks

Pharmaceutical Preparations Industry

369th out of 612 stocks

3.3 Analyst's Opinion

Consensus Rating
Marker Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.50, Marker Therapeutics has a forecasted upside of 310.6% from its current price of $2.07.
Amount of Analyst Coverage
Marker Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Marker Therapeutics has received 62 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Marker Therapeutics has received 68 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Marker Therapeutics has received 52.31% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Marker Therapeutics and other stocks. Vote “Outperform” if you believe MRKR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRKR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Marker Therapeutics does not currently pay a dividend.
Dividend Growth
Marker Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Marker Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 30.90% of the stock of Marker Therapeutics is held by insiders.
Percentage Held by Institutions
Only 29.42% of the stock of Marker Therapeutics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Marker Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Marker Therapeutics is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Marker Therapeutics is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Marker Therapeutics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MRKR

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.markertherapeutics.com

Phone713-400-6400

Employees28

Debt

Debt-to-Equity RatioN/A

Current Ratio5.03

Quick Ratio5.03

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$210,000.00

Price / Sales473.39

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.96 per share

Price / Book2.16

Profitability

EPS (Most Recent Fiscal Year)($0.47)

Net Income$-21,430,000.00

Net MarginsN/A

Return on Equity-68.00%

Return on Assets-54.26%

Miscellaneous

Outstanding Shares48,025,000

Market Cap$99.41 million

Next Earnings Date3/11/2021 (Estimated)

OptionableOptionable

$2.07

-0.06 (-2.82 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive MRKR News and Ratings via Email

Sign-up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.

Marker Therapeutics (NASDAQ:MRKR) Frequently Asked Questions

How has Marker Therapeutics' stock been impacted by COVID-19?

Marker Therapeutics' stock was trading at $1.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRKR shares have increased by 4.5% and is now trading at $2.07.
View which stocks have been most impacted by COVID-19.

Is Marker Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Marker Therapeutics stock.
View analyst ratings for Marker Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Marker Therapeutics?

Wall Street analysts have given Marker Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Marker Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Marker Therapeutics' next earnings date?

Marker Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Marker Therapeutics.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) issued its earnings results on Monday, November, 9th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.01.
View Marker Therapeutics' earnings history.

What price target have analysts set for MRKR?

5 brokerages have issued 12-month target prices for Marker Therapeutics' shares. Their forecasts range from $2.50 to $16.00. On average, they anticipate Marker Therapeutics' stock price to reach $8.50 in the next year. This suggests a possible upside of 310.6% from the stock's current price.
View analysts' price targets for Marker Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Marker Therapeutics' key competitors?

Some companies that are related to Marker Therapeutics include BeyondSpring (BYSI), Aldeyra Therapeutics (ALDX), ANI Pharmaceuticals (ANIP), TFF Pharmaceuticals (TFFP), Avadel Pharmaceuticals (AVDL), BioVie (BIVI), Marinus Pharmaceuticals (MRNS), Athersys (ATHX), Selecta Biosciences (SELB), Cue Biopharma (CUE), Aeglea BioTherapeutics (AGLE), Concert Pharmaceuticals (CNCE), Immunic (IMUX), Catalyst Pharmaceuticals (CPRX) and CytomX Therapeutics (CTMX).
View all of MRKR's competitors.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

Who are Marker Therapeutics' key executives?

Marker Therapeutics' management team includes the following people:

Mr. Peter L. Hoang MBA, Pres, CEO & Director (Age 48, Pay $451.67k)
Mr. Anthony H. Kim, Chief Financial Officer (Age 44, Pay $431.52k)
Dr. Juan F. Vera M.D., Chief Devel. Officer & Director (Age 40)
Dr. Mythili Koneru M.D., Ph.D., Chief Medical Officer (Age 42, Pay $405.11k)
Mr. Michael J. Loiacono, Chief Accounting Officer, Treasurer & Sec. (Age 54)
Ms. Elizabeth Donnelly, Director of Admin.
Ms. Shelia Sterr, Director of HR & Fin.
Dr. Robert Z. Florkiewicz Sr., Sr. Director of Molecular Biology & Virology

What is Marker Therapeutics' stock symbol?

Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR."

Who are Marker Therapeutics' major shareholders?

Marker Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vigilare Wealth Management (0.30%).
View institutional ownership trends for Marker Therapeutics.

Which major investors are buying Marker Therapeutics stock?

MRKR stock was bought by a variety of institutional investors in the last quarter, including Vigilare Wealth Management.
View insider buying and selling activity for Marker Therapeutics or or view top insider-buying stocks.

How do I buy shares of Marker Therapeutics?

Shares of MRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Marker Therapeutics' stock price today?

One share of MRKR stock can currently be purchased for approximately $2.07.

How big of a company is Marker Therapeutics?

Marker Therapeutics has a market capitalization of $99.41 million and generates $210,000.00 in revenue each year. The company earns $-21,430,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Marker Therapeutics employs 28 workers across the globe.

What is Marker Therapeutics' official website?

The official website for Marker Therapeutics is www.markertherapeutics.com.

How can I contact Marker Therapeutics?

Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The company can be reached via phone at 713-400-6400 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here